Widened difference of incidence and survival between different races in epithelial ovarian cancer: a period analysis.

Abstract Introduction To describe the incidence and relative survival in women with epithelial ovarian cancer (EOC) in a population-based cohort in the four decades after diagnosis. EOC is the major pathological type of all ovarian cancers, however, there is limited information on changes of long-term survival in EOC in the four decades. Methods We extracted the incidence and relative survival data from Surveillance, Epidemiology, and End Results (SEER) registries to assess epidemiological changes of patients with EOC from 1974 to 2013. The survival disparities of patients with EOC among four decades, age, race, and socioeconomic status (SES) were performed by Kaplan-Meier curves. Results The overall incidence of EOC gradually declined from 11.4 to 9.0 per 100,000 in the past four decades. The median survival increased from 27 months in the first decades to 48 months in the fourth decade, with 5-year relative survival rate (RSR) improving from 32.3% to 44.3% in the same period. However, the median survival differences increased from 11 months to 18 months between Whites and Blacks and increased from 7 months to 12 months between low-poverty group and high-poverty group respectively over the past four decades. Discussion This study indicated that the incidence and RSR of EOC patients had improved in the past four decades. But the survival gap between different races and SES gradually widened. More importantly, this study will promote the improvement of health care system and clinical management to erase the survival differences in SES groups and races identified in this study, thereby optimize the clinical outcome.

Download Full-text

Period Analysis of Intraracial Differences in Incidence and Survival Rates in Epithelial Ovarian Cancer

Computational and Mathematical Methods in Medicine ◽

10.1155/2021/8032209 ◽

2021 ◽

Vol 2021 ◽

pp. 1-10

Author(s):

Lili Han ◽

Sulaiya Husaiyin ◽

Jing Liu ◽

Miherinisha Maimaiti ◽

Mayinuer Niyazi ◽

...

Keyword(s):

Ovarian Cancer ◽

Survival Rate ◽

Epithelial Ovarian Cancer ◽

Median Survival ◽

Survival Rates ◽

Relative Survival ◽

Population Based ◽

Relative Survival Rate ◽

Kaplan Meier ◽

The Difference

Background. To explain the difference in the incidence and relative survival in a population-based cohort of women with epithelial ovarian cancer (EOC) postdiagnosis in the last forty years. EOC is the most common type of all ovarian cancers, but there is inadequate information about the variations related to long-term EOC survival. Methods. We acquired the incidence and relative survival rate data from the Surveillance, Epidemiology, and End Results (SEER) registries to analyze the epidemiological variations from 1974 to 2013 in EOC-affected individuals. The survival disparities in EOC-specific individuals due to age, race, and socioeconomic status (SES) were performed by Kaplan-Meier analysis. The Results. The overall incidence of EOC progressively declined to 9.0 per 100,000 from 11.4 in the last forty years. The median survival rate improved to 48 months in the first decade from a previous of 27 months in the fourth decade. The 5-year relative survival rate (RSR) increased to 44.3% that was previously 32.3% at the same time. However, between whites and blacks, an increase from 11 to 18 months was observed in the median survival differences. Between the low and high poverty groups, it was increased from 7 months to 12 months, respectively. Conclusions. The incidence rate of RSR and EOC-specific individuals in the last forty years was improved. However, the survival rates among different races and SES differed over time.

Download Full-text

Interpreting Survival Differences and Trends

Tumori Journal ◽

10.1177/030089169708300105 ◽

1997 ◽

Vol 83 (1) ◽

pp. 9-16 ◽

Cited By ~ 26

Author(s):

Franco Berrino ◽

Andrea Micheli ◽

Milena Sant ◽

Riccardo Capocaccia

Keyword(s):

Early Diagnosis ◽

Survival Data ◽

Survival Rates ◽

Relative Survival ◽

Cancer Registries ◽

Population Based ◽

Disease Stage ◽

Definition Of ◽

Survival Differences ◽

Over Time

Since 1990 a concerted action between European population-based cancer registries (the EUROCARE project) has been carried out with the aims of establishing whether there are differences in cancer patient survival in Europe, and the reasons for such differences. Survival differences actually exist for cancer sites for which the stage of disease at diagnosis is the major prognostic factor (such as breast, stomach and colon cancer). However, for most cancer sites, survival increases over time and the survival rates of different countries tend to converge towards higher values. Interpreting survival differences and trends is not an easy task. Longer survival may be achieved by postponing death through better treatment or by anticipating diagnosis. However, an earlier diagnosis may or may not make a treatment more effective in postponing death. The computation of stage-specific or stage-adjusted survival is not sufficient for interpretation of survival differences, because staging procedures change over time and may vary in different hospitals and countries. In addition to an early diagnosis and more effective treatment, a number of factors may bias survival estimates. They may be classified into factors that can be controlled in the analysis (at least partially), such as mortality from other causes, demographic factors, epoch of diagnosis, different statistical methodology, and factors depending on the validity of cancer registry data, such as definition of the illness, exhaustiveness and quality of registration, completeness of follow-up, definition of the date of diagnosis, and definition of disease stage including the diagnostic procedure used to establish stage. To help disentangle the effects of early diagnosis and better treatment, several statistical approaches are being developed: multivariate analysis on relative survival data, new modeling analysis to separately estimate the proportion of cured patients and the length of survival for those patients destined to die, and the standardized collection of information on stage at diagnosis and staging procedures.

Download Full-text

Cancer survival in Cali, Colombia: A population-based study, 1995-2004

Colombia Medica ◽

10.25100/cm.v45i3.1525 ◽

2014 ◽

pp. 110-116 ◽

Cited By ~ 7

Author(s):

Luis Eduardo Bravo ◽

Luz Stella García ◽

Paola Andrea Collazos

Keyword(s):

Prostate Cancer ◽

Lung Cancer ◽

Stomach Cancer ◽

Survival Data ◽

Cancer Survival ◽

Relative Survival ◽

Population Based ◽

Cervix Uteri ◽

Limited Information ◽

Cure Fraction

Background: There is limited information on population-based cancer survival data in Latin America. Objetive: To obtain estimates of survival for some cancers recognized as a public health priority in Colombia using data from the Cancer Registry of Cali for 1995-2004. Methods: All cancer cases for residents of Cali were included for the following sites: breast (3,984), cervix uteri (2,469), prostate (3,999), stomach (3,442) and lung (2,170). Five-year relative survival estimates were calculated using the approach described by Estève. Results: Five-year relative survival was 79% in patients with prostate cancer and 68% and 60% in women with breast or cervix uteri cancer, respectively. The cure fraction was 6% in subjects with lung cancer and 15% in those with stomach cancer. The probability of dying from breast or prostate cancer in people in the lower socio-economic strata (SES) was 1.8 and 2.6 times greater, respectively, when compared to upper SES, p <0.001. Excess mortality associated with cancer was independent of age in prostate or breast cancer. After adjusting for age, sex and SES, the risk of dying from breast, cervix uteri, prostate and lung cancer during the 2000-2004 period decreased 19%, 13%, 48% and 16%, respectively, when compared with the period of 1995-1999. There was no change in the prognosis for patients with stomach cancer. Conclusions: Survival for some kinds of cancer improved through the 1995-2004 period, however health care programs for cancer patients in Cali are inequitable. People from lower SES are the most vulnerable and the least likely to survive.

Download Full-text

No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands

European Journal of Cancer ◽

10.1016/j.ejca.2017.10.030 ◽

2018 ◽

Vol 88 ◽

pp. 31-37 ◽

Cited By ~ 36

Author(s):

M. Timmermans ◽

G.S. Sonke ◽

K.K. Van de Vijver ◽

M.A. van der Aa ◽

R.F.P.M. Kruitwagen

Keyword(s):

Ovarian Cancer ◽

The Netherlands ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Population Based ◽

Term Survival ◽

Population Based Study ◽

Long Term Survival

Download Full-text

Long-Term Survival of Patients with Apparent Early-Stage (FIGO I–II) Epithelial Ovarian Cancer: A Population-Based Study

Gynecologic and Obstetric Investigation ◽

10.1159/000096435 ◽

2006 ◽

Vol 63 (3) ◽

pp. 132-136 ◽

Cited By ~ 4

Author(s):

Patrick Petignat ◽

Daniel de Weck ◽

Frederic Goffin ◽

Georges Vlastos ◽

Reto Obrist ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Early Stage ◽

Population Based ◽

Term Survival ◽

Population Based Study ◽

Long Term Survival

Download Full-text

Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960–2014: A population-based cohort study

BMC Cancer ◽

10.1186/s12885-021-08169-w ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Pia Leandersson ◽

Thomas Hogberg ◽

Paul W. Dickman ◽

Susanne Malander ◽

Christer Borgfeldt

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Fallopian Tube ◽

Relative Survival ◽

Population Based ◽

Serous Carcinoma ◽

Tumor Site ◽

Fallopian Tube Cancer ◽

Oncological Treatment ◽

Pelvic Cancer

Abstract Background Despite improved surgical and oncological treatment, ovarian cancer continues to be the most lethal of the gynecologic malignancies. We aimed to analyze survival trends in epithelial ovarian cancer with regard to age, tumor site, and morphology in Sweden 1960 to 2014. Methods A nationwide population-based study was conducted using data from the Swedish Cancer Registry on 46,350 women aged 18 or older with a diagnosis of epithelial ovarian, fallopian tube, peritoneal, or undesignated abdominal/pelvic cancer 1960 to 2014. Analyses of age-standardized incidence and relative survival (RS) were performed and time trends modelled according to age, tumor site, and morphology. Results Overall incidence of ovarian, tubal, peritoneal, and undesignated abdominal/pelvic cancers declined since 1980. Median age at diagnosis increased. Serous carcinoma increased in incidence. RS at 1, 2 and 5 years from diagnosis improved since 1960, although not for the youngest and the oldest patients. Ten-year RS did not improve. The best RS was found for fallopian tube cancer and the worst RS for undesignated abdominal/pelvic cancer. Among the morphologic subgroups, endometrioid carcinoma had the best RS. Conclusions Survival in epithelial ovarian, tubal, peritoneal, and undesignated abdominal/pelvic cancers in Sweden has improved over the last six decades. Advances in epithelial ovarian cancer treatment have extended life for the first 5 years from diagnosis but 10-year survival remains poor.

Download Full-text